Reviewer’s report

Title: Effect of dabrafenib on melanoma cell lines harboring the BRAFV600D/R mutations

Version: 2 Date: 1 August 2012

Reviewer: Richard K Kefford

Reviewer’s report:

Gentilcore et al BMC Cancer
This is a useful short communication describing sensitivity of melanoma cell lines with two of the rarer but nonetheless clinically important BRAF mutations in melanoma, V600D and V600R.

Comments:
The Abstract does not summarise the results of the paper or emphasise the main novel findings regarding V600D and R mutants

The paper needs some correction of English grammar (e.g. “Despite this compound has been reported to specifically acts on BRAFV600E/K mutants..”, “..allowing to increase the number of melanoma patients who may benefit of a more effective targeted treatment”), and spelling (e.g. “phosphorilated”)


It would be helpful to refer to the largest series of BRAF melanoma mutations which gives more precise incidence of rarer mutations, and shows that together, V600D, R and other rare mutations comprise 8% of BRAF mutations (Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clin Cancer Res. 2012;18:3242-9).

Level of interest: An article whose findings are important to those with closely
related research interests

**Quality of written English:** Needs some language corrections before being published

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests